Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing

Reuters03-17
Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing

Innogen said it has submitted a filing application for the proposed conversion of all its domestic unlisted shares into H shares. The company plans to apply for the listing of, and permission to deal in, the converted H shares on the Hong Kong Stock Exchange’s Main Board. Innogen said the filing procedures are not yet complete and the implementation plan has not been finalised. It added that no shareholders’ meeting is required to approve the conversion and listing under its articles of association.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260317-12055890), on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment